Eden Research plc, a UK-listed company focused on sustainable biopesticides for agriculture, released its interim results for the first half of 2024. The company reported increased revenue of £1.9 million, a 65% growth compared to the same period in 2023. This growth was driven by increased product sales across their existing portfolio and commercial partnerships. Despite a slight increase in operating loss, the company is on track to meet its market expectations for revenue and operating loss for the full year.
Eden Research highlighted its expanding regulatory approvals in key territories, including the authorization of Mevalone® in California, the US, and label expansion in Spain, Germany, and the Czech Republic. The company also announced the appointment of new executives and directors, strengthening its financial position and team.
The companys development pipeline remains active, utilizing its proprietary terpene technology and microencapsulation technology, SustaineÃ’. Eden Research is working towards regulatory submissions for its new bioinsecticide in the US and Europe, with potential first sales in 2025.
Overall, Eden Research plc remains confident in its future success and is committed to creating sustainable solutions for global agrochemicals, animal health, and consumer product industries.